Distinguished in Acute Myeloblastic Leukemia without Maturation

Dr. Margaret R. Odonnell

Hematology Oncology | Hematology | Oncology
1825 Olive Ave, 
South Pasadena, CA 
Distinguished in Acute Myeloblastic Leukemia without Maturation
1825 Olive Ave, 
South Pasadena, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Margaret Odonnell is a Hematologist Oncology specialist and a Hematologist in South Pasadena, California. Dr. Odonnell is rated as a Distinguished provider by MediFind in the treatment of Acute Myeloblastic Leukemia without Maturation. Her top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Acute Myeloblastic Leukemia with Maturation, Bone Marrow Aspiration, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 30 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in CA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

1825 Olive Ave, South Pasadena, CA 91030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: October 07, 2025
Intervention Type: Drug, Biological
Study Drugs: Ixazomib, Lenalidomide, Dexamethasone
Study Phase: Phase 2
A Phase 2 Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Ph+ ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)
A Phase 2 Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Ph+ ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Blinatumomab, Dasatinib, Mercaptopurine, Methotrexate, Methotrexate Sodium, Prednisone, Vincristine, Vincristine Sulfate
Study Phase: Phase 2
S1312, A Phase I Study of Inotuzumab Ozogamicin (NSC-772518) in Combination With CVP (Cyclophosphamide, Vincristine, Prednisone) for Patients With Relapsed/Refractory CD22-Positive Acute Leukemia (Including B-ALL, Mixed Phenotypic Leukemia, and Burkitt's Leukemia)
S1312, A Phase I Study of Inotuzumab Ozogamicin (NSC-772518) in Combination With CVP (Cyclophosphamide, Vincristine, Prednisone) for Patients With Relapsed/Refractory CD22-Positive Acute Leukemia (Including B-ALL, Mixed Phenotypic Leukemia, and Burkitt's Leukemia)
Enrollment Status: Completed
Publish Date: May 03, 2023
Intervention Type: Drug, Other, Biological
Study Drugs: Cyclophosphamide, Vincristine sulfate, Prednisone, Inotuzumab ozogamicin
Study Phase: Phase 1
View 2 Less Clinical Trials
Similar Doctors
Distinguished in Acute Myeloblastic Leukemia without Maturation
Dr. Anthony S. Stein
Hematology | Hematology Oncology | Oncology
Distinguished in Acute Myeloblastic Leukemia without Maturation
Dr. Anthony S. Stein
Hematology | Hematology Oncology | Oncology

City Of Hope Medical Foundation

1500 Duarte Rd, 
Duarte, CA 
 (9.6 miles away)
626-256-4673
Languages Spoken:
English
See accepted insurances

Anthony Stein is a Hematologist and a Hematologist Oncology provider in Duarte, California. Dr. Stein is rated as an Elite provider by MediFind in the treatment of Acute Myeloblastic Leukemia without Maturation. His top areas of expertise are Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Leukemia, Bone Marrow Transplant, and Bone Marrow Aspiration.

Distinguished in Acute Myeloblastic Leukemia without Maturation
Dr. Amandeep Salhotra
Hematology | Hematology Oncology | Oncology
Distinguished in Acute Myeloblastic Leukemia without Maturation
Dr. Amandeep Salhotra
Hematology | Hematology Oncology | Oncology

City Of Hope Medical Foundation

1500 Duarte Rd, 
Duarte, CA 
 (9.6 miles away)
626-256-4673
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Amandeep Salhotra is a Hematologist and a Hematologist Oncology provider in Duarte, California. Dr. Salhotra is rated as an Elite provider by MediFind in the treatment of Acute Myeloblastic Leukemia without Maturation. His top areas of expertise are Graft Versus Host Disease (GvHD), Chronic Graft Versus Host Disease (cGvHD), Acute Myeloid Leukemia (AML), Bone Marrow Aspiration, and Bone Marrow Transplant.

Distinguished in Acute Myeloblastic Leukemia without Maturation
Dr. Vinod A. Pullarkat
Hematology | Hematology Oncology
Distinguished in Acute Myeloblastic Leukemia without Maturation
Dr. Vinod A. Pullarkat
Hematology | Hematology Oncology

City Of Hope Medical Foundation

209 Fair Oaks Ave, 
South Pasadena, CA 
 (1.5 miles away)
626-396-2900
Languages Spoken:
English
See accepted insurances

Vinod Pullarkat is a Hematologist and a Hematologist Oncology provider in South Pasadena, California. Dr. Pullarkat is rated as an Elite provider by MediFind in the treatment of Acute Myeloblastic Leukemia without Maturation. His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Odonnell's expertise for a condition
ConditionClose
    View All 37 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile